期刊文献+

基于药物体内处置的生物药剂学分类系统(BDDCS)简介 被引量:4

Introduction to biopharmaceutics drug disposition classification system (BDDCS)
原文传递
导出
摘要 基于药物体内处置的生物药剂学分类系统将目前FDA现行的生物药剂学分类系统作以改进,使用药物体内代谢程度作为渗透性的替代指标,对药物进行分类。该系统不但可以补充现有仿制药物生物等效性豁免的评审标准,还可以对药物在体内的各种特征进行预测。本文将对该系统作以详细的介绍,在此基础上着重探讨药物转运体在药物体内分布中的作用。 Biopharmaceutics drug disposition classification system (BDDCS) is a modified system based on current FDA biopharmaceutics classification system, using metabolism as a surrogate indicator for absorption, to classify highly permeable drugs. BDDCS could not only be a supplement to the FDA' s biowaiver criteria for the generic drugs, but could also make predictions of drug in vivo profiles. In this review, we will make detailed introduction to the BDDCS system, and drug transporters involved in drug disposition.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第4期265-272,共8页 Chinese Journal of New Drugs and Clinical Remedies
关键词 生物药剂学 溶解性 渗透性 biopharmaceutics solubility permeability
  • 相关文献

参考文献33

  • 1AMIDON GL, LENNERNAS H, SHAH VP, et aL A theoretical basis for a biophannaceulic drug classification: The cmTelation of in vitro drug product dissolution anti in vivo bioavailability[J].PharmRes, 1995, 12(3): 413-420.
  • 2CDER, U.S. Food and Drug Administration. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System[EB/OL]. (2000-08-01) [2010-09-15]. http://www.fda.gov/Drugs/GuidanceCompliance Regulatorylnformation/Guidances/ucm064964.html.
  • 3WU CY, BENET LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and develop- ment of a Biopharmaceutics Drug Disposition Classification System[J]. Pharm Res, 2005, 22(1 ) : 11-23.
  • 4LENNERNAS H. Intestinal permeability and its relevance for absorption and elimination[J]. Xenobiotica, 2007, 37(10): 1015- 1051.
  • 5BENET LZ, AMIDON GL, BARENDS DM, et ol. The use of BDDCS in classifying the permeability of marketed drugs [J]. Pharm Res, 2008, 52(3): 483-488.
  • 6CHMP, European Medicines Agency. Guideline on the investigation of bioequivalenee[EB/OL]. (2010-01-20) [2011- 07 -14]. http://www.ema.europa.eu/ema/index.jsp?curl =pages/ regulation/general/general_eontent_000370.jsp&mid =WC0b01ac 0580032ec5.
  • 7BENET LZ, BROCCATELLI F, OPREA TI. BDDCS applied to over 900 drugs[J]. AAPS J, 2011, 13(4) : 519-547.
  • 8CHEN ML, YU LX. The use of drug metabolism for prediction of intestinal permeability[J], Mol Pharm, 2009, 6(1): 74-81.
  • 9BENET LZ, LARREGIEU CA. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted[J]. Clin Pharmacol Ther, 2010, 88(3): 405-407.
  • 10GIACOMINI KM, HUANG SM, TWEEDIE DJ, et ol. Membrane transporters in drug development[J]. Nat Rev Drug Discov, 2010, 9(3) : 215-236.

同被引文献72

  • 1于香安,蔡怀友.用电子计算器求算片剂溶出度溶出参数的运算程序[J].中国药房,1995,6(4):21-22. 被引量:102
  • 2石莹.HPLC测定小柴胡汤丸中黄芩苷的含量[J].中成药,2007,29(7). 被引量:12
  • 3FDA. Innovation or stagnation:Challenge and opportunity on the critical path to new medical products[ S]. 2004.
  • 4AMIDON GL,LENNERN SH,SHAH VP,et al. A theoretical ba- sis for a biopharmaceutic drug classification : the correlation of in vitro drug product dissolution and in vivo bioavailability [ J ]. Pharm Res,1995 ,12( 3 ) :413 -420.
  • 5WU C,BENET LZ. Predicting drug disposition via application of BCS :transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system [ J ]. Pharm Res,2005,22( 1 ) :11 -23.
  • 6CDER,FDA. Guidance for Industry:Waiver of in vivo bioavail- ability and bioequivalenee studies for immediated-release solid o- ral dosage forms based on a Biopharmaeeuties Classification Sys- tem [ S/OL]. 02/2004 [ 2014 - 07 - 23 ].
  • 7BENET LZ,AMIDON GL,BARENDS DM,et al. The use of BD- DCS in classifying the permeability of marketed drugs[ J]. Pharm Res ,2008,25 (3) :483 - 488.
  • 8CHMP, EMA. Guideline on the investigation of bioequivalenee [S/OL]. 04/2011 [2014-07-23].
  • 9CHEN M,AMIDON GL,BENET LZ,et al. The BCS,BDDCS, and Regulatory Guidances[ J ]. Pharm Res ,2011,28 ( 7 ) : 1774 - 1778.
  • 10LIU W, OKOCHI H, BENET LZ,et al. Sotalol permeability in cuhured-cell, rat intestine, and PAMPA system [ J ]. Pharm Res, 2012,29(7) :1768 - 1774.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部